Edition:
United Kingdom

People: Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

20.88USD
18 Apr 2019
Change (% chg)

$0.08 (+0.38%)
Prev Close
$20.80
Open
$20.73
Day's High
$21.00
Day's Low
$19.80
Volume
334,708
Avg. Vol
598,564
52-wk High
$54.61
52-wk Low
$11.50

Atwood, Brian 

Mr. Brian G. Atwood is Independent Director of the Company. He is President and CEO as well as a co-founder of Cell Design Labs, Inc., a biotechnology company focused on developing human cell engineering technology for the treatment of multiple diseases, including cancer. In 1999, he co-founded and currently serves as a Managing Director for Versant Ventures, a healthcare-focused venture capital firm. Prior to founding Versant Ventures, Mr. Atwood served as a general partner of Brentwood Associates, a venture capital firm. Mr. Atwood also serves on the boards of several pharmaceutical and biotechnology companies, including Atreca, Inc., Immune Design Corp. (NASDAQ: IMDZ), OpGen, Inc. (NASDAQ: OPGN), PhaseRx, Inc., and Veracyte, Inc (NASDAQ: VCYT). Mr. Atwood also served on the boards of Five Prime Therapeutics (NASDAQ: FPRX), Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) acquired in 2014, Helicos Biosciences (NASDAQ: HLCS), Pharmion Corporation (acquired in 2008) and Trius Therapeutics, Inc. (NASDAQ: TSRX) acquired in 2013. Mr. Atwood holds a B.S. in biological sciences from the University of California, Irvine, a M.S. in ecology from the University of California, Davis, and an M.B.A. from Harvard University.

Basic Compensation

Total Annual Compensation, USD 62,500
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 439,579
Fiscal Year Total, USD 502,079

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

M. James Barrett

533,329

Patrick Mahaffy

8,726,480

Daniel Muehl

1,861,090

Gillian Ivers-Read

2,383,880

Lindsey Rolfe

2,429,680

Robert Azelby

--
As Of  31 Dec 2017